Výsledky vyhledávání - "Landon Carter Brown"

Clinical outcomes in patients with metastatic renal cell carcinoma and brain metastasis treated with ipilimumab and nivolumab

Autor: Kunal Desai, Emily N. Kinsey, Moshe Chaim Ornstein, Wei Wei, Daniel J. George, Tian Zhang, Landon Carter Brown, Brian I. Rini, Chester Kao

Publikováno v: Journal for ImmunoTherapy of Cancer, Vol 9, Iss 9 (2021)

The combination of ipilimumab plus nivolumab (I+N) has greatly improved outcomes in patients with intermediate or poor-risk untreated metastatic renal cell carcinoma (mRCC). However, little is known about the outcomes of patients with brain metastasi

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2007616bc60aa5fe82e16fc8b0cc1bbc
https://pubmed.ncbi.nlm.nih.gov/34518292

Zobrazit plný text záznamu

LRP1B mutations are associated with favorable outcomes to immune checkpoint inhibitors across multiple cancer types

Autor: Daniel J. George, Michael R. Harrison, Ramy Sedhom, Tian Zhang, Matthew D Tucker, Jason Zhu, Eric B Schwartz, Daniele Marin, Ajjai Alva, Rajan T. Gupta, Landon Carter Brown, Matthew Labriola, Andrew J. Armstrong, Yuan Wu, Chester Kao, Emmanuel S. Antonarakis, Santosh Gupta

Publikováno v: Journal for Immunotherapy of Cancer
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 3 (2021)

BackgroundLow-density lipoprotein receptor-related protein 1b (encoded by LRP1B) is a putative tumor suppressor, and preliminary evidence suggests LRP1B-mutated cancers may have improved outcomes with immune checkpoint inhibitors (ICI).MethodsWe cond

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::97ab2b7b77eaa9722d34b1992b01de23
http://europepmc.org/articles/PMC7929846

Zobrazit plný text záznamu

Interrelation of functional homologous recombination deficiency and hrr pathway alterations in prostate cancer

Autor: Jason Zhu, Sherif Mohamed El-Refai, Elizabeth Mauer, Benjamin D. Leibowitz, Landon Carter Brown, Claud Grigg, James T Kearns, Justin T. Matulay, Peter E Clark, Derek Raghavan, Earle F Burgess

Publikováno v: Journal of Clinical Oncology. 40:151-151

151 Background: The use of PARP inhibitors (PARPi) may trigger synthetic lethality of tumor cells in the context of deficient homologous recombination repair (HRR). Approximately 10-20% of patients with prostate cancer harbor mutations in the HRR pat

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::832ef2deae87f2f6b4809f619ab597ea
https://doi.org/10.1200/jco.2022.40.6_suppl.151

Zobrazit plný text záznamu

Efficacy of the PD-L1 inhibitor avelumab in neuroendocrine or aggressive variant prostate cancer: Results from a phase II, single-arm study

Autor: Michael S. Humeniuk, Catrin Davies, Monika Anand, Susan Halabi, Andrew J. Armstrong, Michael R. Harrison, Tian Zhang, Jiaoti Huang, Daniel J. George, Landon Carter Brown, Yuan Wu, Taofik Oyekunle

Publikováno v: Journal of Clinical Oncology. 39:89-89

89 Background: Men with metastatic neuroendocrine/small cell and aggressive variant prostate cancer (NEPC/AVPC) have poor outcomes despite platinum and taxane chemotherapy. These tumors share common features with small cell lung cancer, including hig

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::c4be10be1a8a08d4a4ecc0725adb04c2
https://doi.org/10.1200/jco.2021.39.6_suppl.89

Zobrazit plný text záznamu

Combination therapy with nivolumab and tyrosine kinase inhibitors in patients with metastatic renal cell carcinoma

Autor: Chester Kao, Michael R. Harrison, Aradhana M. Venkatesan, Daniel J. George, Tian Zhang, Andrew Leonard Laccetti, Paul G. Corn, Amado J. Zurita, Minas P. Economides, Andrew J. Armstrong, Nizar M. Tannir, Eric Jonasch, Landon Carter Brown, Emily N. Kinsey, Pavlos Msaouel, Benjamin Garmezy, Amishi Yogesh Shah, Matthew T. Campbell

Publikováno v: Journal of Clinical Oncology. 38:e17090-e17090

e17090 Background: Two immunotherapy (IO) and tyrosine kinase inhibitor (TKI) combinations are FDA-approved for patients (pts) with metastatic renal cell carcinoma (mRCC). Here we present a multicenter off-protocol experience with IO/TKI combinations

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::1a15228ecfe68f1ca33c2d04b2e7d41b
https://doi.org/10.1200/jco.2020.38.15_suppl.e17090

Zobrazit plný text záznamu

Association of LRP1B pathogenic genomic alterations with favorable outcomes with immune checkpoint inhibitors across multiple tumor types

Autor: Yuan Wu, Matthew Labriola, Andrew J. Armstrong, Chester Kao, Rajan T. Gupta, Jason Zhu, Michael R. Harrison, Ajjai Alva, Daniele Marin, Daniel J. George, Ramy Sedhom, Landon Carter Brown, Tian Zhang, Emmanuel S. Antonarakis, Matthew D Tucker, Eric B Schwartz

Publikováno v: Journal of Clinical Oncology. 38:3007-3007

3007 Background: Low-density lipoprotein receptor-related protein 1b (LRP1b) is a putative tumor suppressor and one of the most frequently altered genes in cancer. Our prior single-center work suggested that LRP1B alterations may enrich for responses

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::6b80461669571ac76c81b1faa172b38a
https://doi.org/10.1200/jco.2020.38.15_suppl.3007

Zobrazit plný text záznamu

CDK12-mutated prostate cancer (PC): Clinical outcomes to standard therapies and immune checkpoint blockade

Autor: Michael Thomas Schweizer, Roman Gulati, Landon Carter Brown, Rana R. McKay, Tanya B. Dorff, Deepak Kilari, Pankaj Vats, Vaibhav G. Patel, William K. Oh, Andrew J. Armstrong, Robert B. Montgomery, Ajjai Shivaram Alva

Publikováno v: Journal of Clinical Oncology. 38:191-191

191 Background: Translational studies have shown that CDK12 mutations may delineate an immunoresponsive subgroup of PC, characterized by high neoantigen burden. Given that these mutations may define a clinically relevant PC subgroup, we sought to des

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::916db2b00cb2769ea13eeb241780e656
https://doi.org/10.1200/jco.2020.38.6_suppl.191

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání